Nadia Waheed

CIK: 0002023884

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (57.1%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OCUL

OCULAR THERAPEUTIX, INC

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

OCUL
OCULAR THERAPEUTIX, INC
Jun 3, 2026
Sale(S)
Direct
14.8K shares at avg. $8.27$123K
OCUL
OCULAR THERAPEUTIX, INC
Feb 20, 2026
Sale(S)
Direct
3.5K shares at avg. $7.74$27K
OCUL
OCULAR THERAPEUTIX, INC
Feb 12, 2026
Sale(S)
Direct
7.9K shares at avg. $9.04$71K
OCUL
OCULAR THERAPEUTIX, INC
Jan 2, 2026
Award(A)
Direct
79.1K shares-
OCUL
OCULAR THERAPEUTIX, INC
Aug 12, 2025
Award(A)
Direct
40.4K shares-
OCUL
OCULAR THERAPEUTIX, INC
Jun 2, 2025
Sale(S)
Direct
13.9K shares at avg. $8.05$112K
OCUL
OCULAR THERAPEUTIX, INC
Feb 11, 2025
Award(A)
Direct
79K shares-

		Type	Shares	Price		Ownership
Jun 3, 2026	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	14,828	$8.27	$122,628	Direct
Feb 20, 2026	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	3,510	$7.74	$27,167	Direct
Feb 12, 2026	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	7,863	$9.04	$71,082	Direct
Jan 2, 2026	OCUL OCULAR THERAPEUTIX, INC	Award(A)	79,112	-	$0	Direct
Aug 12, 2025	OCUL OCULAR THERAPEUTIX, INC	Award(A)	40,363	-	-	Direct
Jun 2, 2025	OCUL OCULAR THERAPEUTIX, INC	Sale(S)	13,861	$8.05	$111,581	Direct
Feb 11, 2025	OCUL OCULAR THERAPEUTIX, INC	Award(A)	79,000	-	-	Direct

1-7 of 7 transactions

About Waheed Nadia

Waheed Nadia (SEC CIK 0002023884) files insider reports with the SEC as Chief Medical Officer of OCULAR THERAPEUTIX, INC (OCUL).

Signal8 holds 7 ownership filings by Waheed Nadia, all Form 4s, filed between Feb 13, 2025 and Jun 5, 2026. Those filings report 7 transactions, from Feb 11, 2025 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Waheed Nadia's filings is in BEDFORD, MA.

Recent filings by Waheed Nadia

Jun 3, 2026: Open-market sale of OCUL shares (Form 4, code S).
Feb 20, 2026: Open-market sale of OCUL shares (Form 4, code S).
Feb 12, 2026: Open-market sale of OCUL shares (Form 4, code S).
Jan 2, 2026: Grant or award of OCUL shares (Form 4, code A).
Aug 12, 2025: Grant or award of OCUL shares (Form 4, code A).

Other insiders filing for OCULAR THERAPEUTIX, INC (OCUL)

Anderman Todd, Chief Legal Officer
Kaiser Peter, Chief Development Officer
Heier Jeffrey S., Chief Scientific Officer
Notman Donald, Chief Operating Officer
Nayak Sanjay, Chief Strategy Officer
Dugel Pravin

How to read Form 4 transaction codes